Impact of the <i>PPAR</i>-γ<i>2</i> Pro12Ala Polymorphism and ACE Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: Evidence From BENEDICT — Salvatore De Cosmo (2009) | RDL Network
Impact of the <i>PPAR</i>-γ<i>2</i> Pro12Ala Polymorphism and ACE Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: Evidence From BENEDICT
Article 2009 en
Authors
SC
Salvatore De Cosmo
NM
Nicola Motterlini
SP
Sabrina Prudente
Abstract
1 min read
In type 2 diabetes, the Ala allele protects from worsening albuminuria and new-onset microalbuminuria, and ACE inhibition blunts the excess risk of microalbuminuria associated with the Pro/Pro genotype. Evaluating Pro12Ala polymorphism may help identifying patients at risk who may benefit the most from early renoprotective therapy.
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.